-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the news of layoffs by Internet giants Tencent and Alibaba has been on the hot search list
.
In the pharmaceutical industry, with the changes in the pharmaceutical market environment and the restructuring of multinational pharmaceutical companies, the wave of layoffs in the pharmaceutical industry has also emerged this year
.
Since 2022, large pharmaceutical companies, including Gilead, Biojian, and Dongpei Pharmaceuticals, have reported layoffs
.
Gilead: Will lay off 114 employees On March 9, Gilead has submitted a layoff notice to Worker Adjustment and Retraining Notification in New Jersey, and will lay off 114 employees in Morris Plains, New Jersey.
The layoffs are planned to be fired in three batches, respectively.
It will take place in April, September and December
.
The first batch of layoffs is scheduled for April 22.
It is reported that Gilead should have notified its employees on or before February 21, before it announced the results of the Trodelvy Phase III clinical trial
.
On March 7, Gilead announced that a Phase III clinical trial of Trodelvy (goxatuzumab) in patients with HR+/HER2- metastatic breast cancer who had received multiple prior therapies met the primary endpoint of progression-free survival ( PFS) was statistically significantly improved
.
The 2021 financial report shows that the company achieved total revenue of $27.
305 billion, an increase of 11% year-on-year
.
R&D investment was US$5.
363 billion, a year-on-year increase of 6.
4%
.
Among them, Trodelvy's first full annual performance was US$380 million, mainly because the proportion of patients with triple-negative breast cancer and urothelial cancer continued to increase.
The drug was also approved by regulatory agencies in the European Union, Australia, and Canada in 2021.
It is expected to further drive sales growth
.
Bojian: It may lay off about 10% of its employees Recently, there have been reports that Bojian has confirmed that it may lay off about 10% of its employees
.
After Biogen's Aduhelm was approved in June 2021, there were concerns about the safety of Aduhelm, which hindered sales of the drug
.
According to Biojian's 2021 financial report released on February 3, Biojian's annual revenue was US$10.
98 billion, a year-on-year decrease of 19%
.
Among them, Aduhelm has only sold $3 million since its listing in June
.
A spokesman for Biogen once revealed: "Biogen is implementing cost reduction measures.
Through layoffs, it is expected to save 500 million US dollars per year
.
" It can be seen that if the company promotes the layoff plan, the purpose is to cut costs
.
It is also reported that in December 2021, Biogen has planned to lay off staff to save expenses
.
At present, more than 100 employees of Biogen have been laid off, of which two-thirds are the business team that enjoys the Alzheimer's disease franchise
.
Dongpei Pharmaceuticals: Disbanding the sales team of Ouxiwei China On March 7, according to news released by various media, the Italian biopharmaceutical company Dongpei Pharmaceuticals has stopped promoting its Senaijiming eye drops (Ouxiwei) in China.
The company has basically disbanded the sales team in China
.
However, the company only retains a small number of medical department personnel in China.
If the hospital needs to use Ouxiwei, it will be provided by Dongpei Pharmaceutical for one-time delivery
.
Oxyvit is primarily used to treat moderate or severe neurotrophic keratitis (NK), a rare disease with an incidence of less than 4.
2/10,000 cases
.
The report shows that about 50% of the patients are already moderately severe at the time of diagnosis, and even severe corneal perforation and blindness
.
Ouxiwei entered the Chinese market for less than two years, but because of its high price and failure to enter the national medical insurance catalog, the market demand for patients who can use the products is limited
.
In addition to disbanding the sales team, it is reported that the "Wei You Lighting" patient welfare project jointly launched by Dongpei Pharmaceuticals and Magnesium Health will also officially end at the end of March 2022
.
According to the data, in addition to the Italian domestic market, the United States and China are also its main strategic markets.
The company's main focus areas are ophthalmology, transplantation, oncology and metabolism
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In the pharmaceutical industry, with the changes in the pharmaceutical market environment and the restructuring of multinational pharmaceutical companies, the wave of layoffs in the pharmaceutical industry has also emerged this year
.
Since 2022, large pharmaceutical companies, including Gilead, Biojian, and Dongpei Pharmaceuticals, have reported layoffs
.
Gilead: Will lay off 114 employees On March 9, Gilead has submitted a layoff notice to Worker Adjustment and Retraining Notification in New Jersey, and will lay off 114 employees in Morris Plains, New Jersey.
The layoffs are planned to be fired in three batches, respectively.
It will take place in April, September and December
.
The first batch of layoffs is scheduled for April 22.
It is reported that Gilead should have notified its employees on or before February 21, before it announced the results of the Trodelvy Phase III clinical trial
.
On March 7, Gilead announced that a Phase III clinical trial of Trodelvy (goxatuzumab) in patients with HR+/HER2- metastatic breast cancer who had received multiple prior therapies met the primary endpoint of progression-free survival ( PFS) was statistically significantly improved
.
The 2021 financial report shows that the company achieved total revenue of $27.
305 billion, an increase of 11% year-on-year
.
R&D investment was US$5.
363 billion, a year-on-year increase of 6.
4%
.
Among them, Trodelvy's first full annual performance was US$380 million, mainly because the proportion of patients with triple-negative breast cancer and urothelial cancer continued to increase.
The drug was also approved by regulatory agencies in the European Union, Australia, and Canada in 2021.
It is expected to further drive sales growth
.
Bojian: It may lay off about 10% of its employees Recently, there have been reports that Bojian has confirmed that it may lay off about 10% of its employees
.
After Biogen's Aduhelm was approved in June 2021, there were concerns about the safety of Aduhelm, which hindered sales of the drug
.
According to Biojian's 2021 financial report released on February 3, Biojian's annual revenue was US$10.
98 billion, a year-on-year decrease of 19%
.
Among them, Aduhelm has only sold $3 million since its listing in June
.
A spokesman for Biogen once revealed: "Biogen is implementing cost reduction measures.
Through layoffs, it is expected to save 500 million US dollars per year
.
" It can be seen that if the company promotes the layoff plan, the purpose is to cut costs
.
It is also reported that in December 2021, Biogen has planned to lay off staff to save expenses
.
At present, more than 100 employees of Biogen have been laid off, of which two-thirds are the business team that enjoys the Alzheimer's disease franchise
.
Dongpei Pharmaceuticals: Disbanding the sales team of Ouxiwei China On March 7, according to news released by various media, the Italian biopharmaceutical company Dongpei Pharmaceuticals has stopped promoting its Senaijiming eye drops (Ouxiwei) in China.
The company has basically disbanded the sales team in China
.
However, the company only retains a small number of medical department personnel in China.
If the hospital needs to use Ouxiwei, it will be provided by Dongpei Pharmaceutical for one-time delivery
.
Oxyvit is primarily used to treat moderate or severe neurotrophic keratitis (NK), a rare disease with an incidence of less than 4.
2/10,000 cases
.
The report shows that about 50% of the patients are already moderately severe at the time of diagnosis, and even severe corneal perforation and blindness
.
Ouxiwei entered the Chinese market for less than two years, but because of its high price and failure to enter the national medical insurance catalog, the market demand for patients who can use the products is limited
.
In addition to disbanding the sales team, it is reported that the "Wei You Lighting" patient welfare project jointly launched by Dongpei Pharmaceuticals and Magnesium Health will also officially end at the end of March 2022
.
According to the data, in addition to the Italian domestic market, the United States and China are also its main strategic markets.
The company's main focus areas are ophthalmology, transplantation, oncology and metabolism
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.